MDA-19

MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.[1][2]

MDA-19
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H23N3O2
Molar mass349.426 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also
  • AM-1221
  • JTE 7-31
  • JWH-019
  • JWH-133
  • N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide

References
  1. Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M (August 2008). "Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain". Journal of Medicinal Chemistry. American Chemical Society. 51 (16): 4932–47. doi:10.1021/jm8002203. PMID 18666769.
  2. Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M (July 2010). "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain". Anesthesia and Analgesia. 111 (1): 99–109. doi:10.1213/ANE.0b013e3181e0cdaf. PMC 3253719. PMID 20522703.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.